Drug trial offers new hope for those with metastatic breast cancer

Scientists are studying whether talazoparib could help treat those with incurable breast cancer

Scientists have launched a new trial that could offer hope to those with incurable breast cancer.

They are studying whether an existing drug, talazoparib, also known by the brandname Talzenna, may offer a new treatment to people with incurable breast cancer that has spread to the brain.

Secondary breast cancer, also known as metastatic breast cancer, occurs when the cancer has spread from the breast to other parts of the body, where it becomes incurable. Last month, it claimed the life of Girls Aloud singer Sarah Harding.

The new trial, funded by the charity Breast Cancer Now, will see researchers assess whether talazoparib could help those with terminal breast cancer. The drug is a PARP inhibitor, which works by preventing cancer cells from repairing, forcing them to die.

Experts from RCSI University of Medicine and Health Sciences in Dublin will use tumours and breast cancer cells donated by patients to see in the lab whether talazoparib is effective in treating secondary breast cancer in the brain. Further tests will examine the drug in mice, as well as models that mimic the brain’s protective system.

“Our previous research has shown that, in many cases, secondary breast cancer tumours in the brain have changes in the way they repair their DNA and we believe this could make them vulnerable to PARP inhibitor drugs like talazoparib,” said Prof Leonie Young, one of the co-leads of the research team.

Natalie Woodford, 57, from Surrey, who was diagnosed with secondary breast cancer in 2017, welcomed the launch of the research.

“It’s really encouraging to learn about the new secondary breast cancer research happening,” she said. “I hope that this study will be a success and lead to new treatments for women like me in the future.”

Dr Simon Vincent, director of research, support and influencing at Breast Cancer Now, added: “An estimated 35,000 people in the UK are living with incurable secondary breast cancer, and the fear and uncertainty around when this devastating disease will cut their lives short.

“We desperately need to discover new ways to treat this incurable disease, including for those whose breast cancer has spread to the brain and who have very limited treatment options.”

Contributor

Andrew Gregory Health editor

The GuardianTramp

Related Content

Article image
Drug combination may extend pancreas cancer survival, trial finds
Liverpool University-led study found mix of two off-patent drugs upped five-year survival rate from 16% to 29% of patients

Sarah Boseley Health editor

03, Jun, 2016 @6:00 PM

Article image
Pfizer to give out breast cancer drug free while awaiting NHS decision
Pharmaceutical firm says it will offer palbociclib to patients while regulator rules on whether it should be available on NHS

Haroon Siddique

04, May, 2017 @2:25 PM

Article image
Drug may help more women survive hereditary breast cancer
International trials of olaparib were stopped early as benefits of ‘groundbreaking’ drug became clear

Sarah Boseley Health editor

03, Jun, 2021 @9:00 PM

Article image
UK regulator approves drug that could extend lives of breast cancer patients
National Institute for Health and Care Excellence gives NHS go-ahead to prescribe eribulin after new evidence shows drug may have ‘substantial’ benefits

Denis Campbell Health policy editor

03, Nov, 2016 @12:01 AM

Drug trial gives hope of longer life to women fighting ovarian cancer

British scientists have developed a drug that could prolong lives of women suffering from ovarian cancer

Denis Campbell, health correspondent

06, Apr, 2009 @11:01 PM

Unpublished data shows breast cancer drug 'third less effective'

Drug trial involving 1,000 women given Herceptin shows drug is not effective as thought

Sarah Boseley, health editor

15, May, 2008 @11:30 PM

Article image
Statins 'could be valuable addition to breast cancer treatment'
Research shows some early tumours can produce molecule made from cholesterol which can mimic oestrogen

Sarah Boseley Health editor

31, May, 2016 @11:01 PM

Article image
'Gamechanging' cancer drug rejected for use on NHS
Nivolumab deemed too expensive for the benefits but cancer specialists urge NHS and manufacturers to reach compromise

Sarah Boseley Health editor

11, Apr, 2017 @5:01 AM

Article image
Night shifts do not increase breast cancer risk, study concludes
UK study covering 100,000 women finds ‘no overall link’ between cancer and night work

Haroon Siddique

28, May, 2019 @11:01 PM

Health: Drug trial hope for men with prostate cancer

New treatment could allow sufferers to work and travel and potentially save lives, say researchers

Sarah Boseley, health editor

21, Jul, 2008 @11:01 PM